Results of the FUSION study will help GILD decide how to handle genotype-3; it may turn out that 16 weeks of treatment does the trick (although I doubt it):
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.